Eli Lilly has a new partnership with the US National Center for Advancing Translational Sciences, reports the Nature News Blog. Lilly is going to screen more than 3,800 approved and investigational drugs that are part of the center's collection, and the company says it will post its results publicly. "This innovative collaboration with Lilly is exactly the type of partnership that NCATS is eager to foster with many other groups from industry, government and academia," said NCATS Acting Director Thomas Insel in a statement.
An NCATS Deal
Mar 15, 2012